Effect on fasting plasma glucose (FPG) of once daily oral administration during 28 days of O304 suspension in subjects with Type 2 Diabetes (T2D). A single-centre, randomised, parallel-group, double-blinded, placebo controlled Phase IIa study (TELLUS).

Trial Profile

Effect on fasting plasma glucose (FPG) of once daily oral administration during 28 days of O304 suspension in subjects with Type 2 Diabetes (T2D). A single-centre, randomised, parallel-group, double-blinded, placebo controlled Phase IIa study (TELLUS).

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs O 304 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms TELLUS
  • Sponsors Betagenon
  • Most Recent Events

    • 02 Nov 2017 Results presented in Betagenon Media Release
    • 21 Oct 2017 Status changed from recruiting to completed.
    • 19 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top